WSJ Your Money Briefing - What’s News in Markets: Amgen’s Prognosis, Quantum Boost, iPhone Makeover

Episode Date: September 12, 2026

Why did a failed Novartis drug trial tank Amgen’s shares? And how is taxpayer money funding quantum-computing companies? Plus, will people pay $2,000 for a foldable iPhone? Host Imani Moise discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Hey listeners, your money briefing is still on a break, but we'll be back with more personal finance information for you in the future. Until then, here's the news moving the markets this week. Hey listeners, it's Saturday, September 12th. I'm Imani Moise for the Wall Street Journal. And this is what's news in markets, our look at the biggest stock moves of the week and the news that drove them. Let's dive in. It was a rough week for stocks, with intensifying pressures from inflation sending the bond market into a tailspin. The war with Iran pushed oil above $100 a barrel, feeling concerns that

higher prices would lead to higher interest rates. The yield on the 10-year treasury climbed to nearly 5 percent, and Friday's inflation report only reinforced expectations that the Federal Reserve will raise rates next week. Higher yields put pressure on the stock market by raising the cost of borrowing, while making relatively safe government bonds more attractive. Still, investors welcome the prospect of the Fed getting inflation under control, helping stocks rebound Friday after four straight days of declines. Overall, the NASDAQ fell two-thirds of a percent for the week, while the SMP 500 lost 0.8 percent, and the Dow finished the week 1.6 percent lower. Health care was the worst-performing sector in the SMP this week, falling more than 3.5 percent after one failed drug trial sent

shockwaves through the industry. Amgen shares plunged 10 percent on Tuesday, for their worst day in more than 25 years. But here's the thing. It wasn't Amgen's drug that failed. Swiss drug maker Novartis said an experimental heart disease treatment failed a late-stage clinical trial. The drug successfully lowered levels of a type of bad cholesterol called LP. Little A. But that didn't translate into fewer heart attacks, strokes, or deaths.

The results from Novartis raised questions about whether lowering LP.A can actually prevent cardiovascular problems. That's potentially bad news for Amgen because it's developing a similar treatment that also works by targeting the same risk factor. One Barclays analyst called the trial results, quote, the worst possible outcome for Amgen. For the week, Amgen and Novartis stock both tumbled more than 13.5%. Some of the standout winners in the stock market this week were quantum computing companies, even though quantum computing itself still isn't ready for prime time.

shares of D-Wave Quantum, Raghetti Computing, and Quintium rallied after a federal agency awarded each company $100 million in exchange for minority stakes in all three. The money is meant to support research and development in quantum computing, which uses physics to tackle complex problems that conventional computers struggle with. The hope is that it could eventually transform industries from medicine to cybersecurity. But today's quantum computers are still limited and prone to errors. The investment is the latest example. of Washington putting taxpayer money behind technologies it considers strategically important. The government already owns 10% of chipmaker Intel, and this week, WSJ exclusively reported that the Pentagon was in talks to lend roughly $5 billion to AI infrastructure startup fluid

stack, by far the largest loan ever considered by the office behind the deal. As for those quantum companies, D-Wave ended the week 1.3% higher, and Raghetti gained about half a percent, while Quintinium gave back its post-announcement gains and finished 1.3% lower. And one number that caught investors' attention this week was 1,99. That's the price in dollars of Apple's new iPhone duo, the company's first foldable phone, and the iPhone's biggest makeover since launching in 2007. It's also Apple's most expensive iPhone ever. costing more than some of its computers. Convincing customers to pay MacBook Pro money for a phone upgrade could be a tough sell,

especially since the category hasn't exactly taken off. Foldable phones have been around for about seven years, but shipments actually fell 15% in the first half of this year. Apple shares slipped by less than half a percent on announcement day, but that's actually pretty typical. Apple stock underperformed the SMP on each of its previous five iPhone reveal days. Historically, investors have tended to warm up to new iPhones in the weeks after their debut. This time, the turnaround came a lot faster.

Apple shares jumped on Thursday after an analyst report said the duo's design could drive stronger than expected demand. On top of that, IDC expects Apple to capture 44% of all foldable phone revenue this year, even though it launches with just three months left to go. Apple shares finish the week up nearly 4%. And Apple supplier, Skyworks, jumped more than 19%. And now you know it's news in markets this week. You can read about more stocks that moved on the week's news in our live markets coverage on WSJ.com.

Today's show is produced by Pierre Bainame with Deputy Editor Chris Zinsley. I'm Imani-Mau-Ease. Have a great weekend. And see you next Saturday.